Shivalik Rasayan Ltd
NSE: SHIVALIK BSE: 539148Pharma
Incorporated in 1979, Shivalik Rasayan Ltd is a manufacturer of Agrochemicals & Active Pharma Ingredients[1]
₹252
52W: ₹207 — ₹653
PE 45.2 · Book ₹254 · -1% vs bookMarket Cap₹396 Cr
Stock P/E45.2Price to Earnings
ROCE4.42%Return on Capital
ROE3.59%Return on Equity
Div. Yield0.19%Face Value ₹5
Strengths
- +Stock is trading at 1.00 times its book value
- +Debtor days have improved from 88.5 to 66.6 days.
- +Company's working capital requirements have reduced from 120 days to 69.9 days
Weaknesses
- −Tax rate seems low
- −Company has a low return on equity of 3.76% over last 3 years.
- −Dividend payout has been low at 6.49% of profits over last 3 years
Shareholding Pattern
Promoters47.37%
FIIs4.2%
DIIs0%
Public48.43%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 47.95% | 47.95% | 47.95% | 47.37%▼0.6 | 47.37% | 47.37% | 47.37% | 47.37% |
| FIIs | 2.15% | 3.28%▲1.1 | 4.33%▲1.1 | 4.28%▼0.0 | 4.36%▲0.1 | 4.38%▲0.0 | 3.9%▼0.5 | 4.2%▲0.3 |
| DIIs | 0.88% | 0.88% | 0.88% | 0.64%▼0.2 | 0.56%▼0.1 | 0.48%▼0.1 | 0.12%▼0.4 | 0%▼0.1 |
| Public | 49% | 47.87%▼1.1 | 46.81%▼1.1 | 47.72%▲0.9 | 47.71%▼0.0 | 47.76%▲0.0 | 48.62%▲0.9 | 48.43%▼0.2 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 23.51 | 23.73 | 23.92 | 31.58 | 37.7 | 40.16 | 39.78 | 46.26 | 46.67 | 35.13 |
| Expenses | 18.49 | 19.76 | 20.39 | 25.65 | 31.25 | 33.55 | 32.41 | 39.9 | 39.79 | 29.18 |
| Operating Profit | 5.02 | 3.97 | 3.53 | 5.93 | 6.45 | 6.61 | 7.37 | 6.36 | 6.88 | 5.95 |
| OPM % | 21.35% | 16.73% | 14.76% | 18.78% | 17.11% | 16.46% | 18.53% | 13.75% | 14.74% | 16.94% |
| Net Profit | 1.17 | 2.31 | 2.56 | 3.07 | 3.46 | 4.02 | 3.33 | 1.22 | 2.19 | 2.03 |
| EPS ₹ | 0.75 | 1.48 | 1.65 | 1.97 | 2.22 | 2.58 | 2.11 | 0.77 | 1.39 | 1.29 |
AI Insights
Revenue Trend
TTM revenue at ₹168Cr, up 12.8% YoY. OPM at 16%.
Debt Position
Borrowings at ₹62Cr. Debt-to-equity ratio: 0.16x. Healthy balance sheet.
Institutional Flow
DIIs: 0% (+0.00pp change). FIIs: 4.2% (+3.85pp change). Promoters hold 47.37%.
Margin & Efficiency
ROCE declining from 23% (Mar 2014) to 4% (Mar 2025). Working capital days: 70.
Valuation
PE 45.2x with 4.42% ROCE. Price is -1% above book value of ₹254. Dividend yield: 0.19%.
Recent Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 13 Apr - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026.
- Closure of Trading Window 26 Mar - Trading window closed Apr 1, 2026 until audited results for year ended Mar 31, 2026 declared.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 17 Feb - Copy of Newspaper Publication for the Unaudited Financial results for the quarter ended on 31.12.2025
- Outcome Of The Board Meeting Held On 13.02.2026 13 Feb - Board approved unaudited Q3 and nine-month results ended 31-Dec-2025; standalone total revenue Rs 3,576.99 lakhs.
- Board Meeting Intimation for Approval Of Quarterly Results For The Quarter Ended And Nine Months Ended On 31.12.2025 4 Feb - Board meeting Feb 13, 2026 to approve unaudited Q3/9M results ended Dec 31, 2025; trading window closed.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse